Purple Biotech (PPBT) Short term Debt (2014)
Purple Biotech's (PPBT) quarterly Short term Debt came in at $294000.0 in Q4 2014, little changed quarter-over-quarter from $294000.0 in Q3 2014.
Powered by 
Analysis
Purple Biotech (PPBT) Short term Debt (2014) Analysis & Trends
Purple Biotech (PPBT) has reported Short term Debt for 1 consecutive years, with $294000.0 the latest figure, recorded in Q4 2014.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $294000.0 in Q4 2014; TTM through Dec 2014 was $294000.0, a N/A change from a year earlier, with the FY2014 full-year figure at $294000.0, changed N/A from the prior year.
- Short term Debt was $294000.0 for Q4 2014 at Purple Biotech, roughly flat from $294000.0 in the prior quarter.
- Over five years, Short term Debt peaked at $294000.0 in Q3 2014 and troughed at $294000.0 in Q3 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn |
| 10 | Purple Biotech | 291,843.46 | 291,843.46 | - |